Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804630152> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2804630152 abstract "Background Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis (PsO). PsA is a chronic inflammatoryarthropathy that affects joints accompanied by inflammation of the skin (PsO). PsO is a common skin condition characterised by scaly red and white patches on the skin. Purpose Demonstrate safety and efficacy of apremilast in PsA and PsO. Material and methods Observational, retrospective and descriptive study of a patient with PsA and another one with PsO in a third-tier hospital. The information has been obtained from the Electronic Clinical History (SELENE®) and the Pharmacy Service Managing Software (FARMATOOLS®). Results Patient 1: 42 years’ old male with PsA was treated with methotrexate and sulfasalazine from 2005 until now. In 2016, he started with 40 mg adalimumab (recombinant human immunoglobulin G1 monoclonal antibody) administered fortnightly as a single dose. Adalimumab was discontinued due to worsening of asthma and began with apremilast which improved the symptoms of PsA and the asthma died out. Patient 2: 39 years’ old female with PsO was treated with methotrexate from 2013 without improvement who started treatment with apremilast, obtained a good therapeutic response with significant improvements in pruritus and skin discomfort/pain. So, apremilast use was authorised as a treatment for PsA and PsO. Apremilast 30 mg twice-daily improved signs and symptoms in both diseases. Conclusion FDA, EMA and AEMPS have approved the use of apremilast for treating PsA and PsO. Apremilast was acceptably safe, effective and tolerated by patients in these clinical cases. Apremilast could also represent a treatment opportunity for patients unresponsive to both systemic and biological agents, or whose treatment was contraindicated. References and/or Acknowledgements Data sheet Apremilast. SELENE®. FARMATOOLS®. No conflict of interest" @default.
- W2804630152 created "2018-06-01" @default.
- W2804630152 creator A5012613732 @default.
- W2804630152 creator A5029135402 @default.
- W2804630152 creator A5031845551 @default.
- W2804630152 creator A5033055030 @default.
- W2804630152 creator A5061355100 @default.
- W2804630152 creator A5064701092 @default.
- W2804630152 creator A5066012872 @default.
- W2804630152 date "2018-03-01" @default.
- W2804630152 modified "2023-10-17" @default.
- W2804630152 title "4CPS-042 Apremilast in psoriatic arthritis and psoriasis: a case report" @default.
- W2804630152 doi "https://doi.org/10.1136/ejhpharm-2018-eahpconf.133" @default.
- W2804630152 hasPublicationYear "2018" @default.
- W2804630152 type Work @default.
- W2804630152 sameAs 2804630152 @default.
- W2804630152 citedByCount "0" @default.
- W2804630152 crossrefType "proceedings-article" @default.
- W2804630152 hasAuthorship W2804630152A5012613732 @default.
- W2804630152 hasAuthorship W2804630152A5029135402 @default.
- W2804630152 hasAuthorship W2804630152A5031845551 @default.
- W2804630152 hasAuthorship W2804630152A5033055030 @default.
- W2804630152 hasAuthorship W2804630152A5061355100 @default.
- W2804630152 hasAuthorship W2804630152A5064701092 @default.
- W2804630152 hasAuthorship W2804630152A5066012872 @default.
- W2804630152 hasBestOaLocation W28046301522 @default.
- W2804630152 hasConcept C126322002 @default.
- W2804630152 hasConcept C16005928 @default.
- W2804630152 hasConcept C2776260265 @default.
- W2804630152 hasConcept C2777575956 @default.
- W2804630152 hasConcept C2780132546 @default.
- W2804630152 hasConcept C2780564577 @default.
- W2804630152 hasConcept C2781059491 @default.
- W2804630152 hasConcept C2781427535 @default.
- W2804630152 hasConcept C71924100 @default.
- W2804630152 hasConceptScore W2804630152C126322002 @default.
- W2804630152 hasConceptScore W2804630152C16005928 @default.
- W2804630152 hasConceptScore W2804630152C2776260265 @default.
- W2804630152 hasConceptScore W2804630152C2777575956 @default.
- W2804630152 hasConceptScore W2804630152C2780132546 @default.
- W2804630152 hasConceptScore W2804630152C2780564577 @default.
- W2804630152 hasConceptScore W2804630152C2781059491 @default.
- W2804630152 hasConceptScore W2804630152C2781427535 @default.
- W2804630152 hasConceptScore W2804630152C71924100 @default.
- W2804630152 hasLocation W28046301521 @default.
- W2804630152 hasLocation W28046301522 @default.
- W2804630152 hasOpenAccess W2804630152 @default.
- W2804630152 hasPrimaryLocation W28046301521 @default.
- W2804630152 isParatext "false" @default.
- W2804630152 isRetracted "false" @default.
- W2804630152 magId "2804630152" @default.
- W2804630152 workType "article" @default.